1     
JAIL DRUG TREATMENT PILOT PROGRAM

2     
2020 GENERAL SESSION

3     
STATE OF UTAH

4     
Chief Sponsor: Carol Spackman Moss

5     
Senate Sponsor: ____________

6     

7     LONG TITLE
8     General Description:
9          This bill creates a pilot program to provide treatment to incarcerated individuals who
10     are addicted to certain substances.
11     Highlighted Provisions:
12          This bill:
13          ▸     defines terms;
14          ▸     creates a pilot program to administer Naltrexone treatment to certain individuals
15     who suffer from alcohol or opiate addiction;
16          ▸     provides that the Commission on Criminal and Juvenile Justice shall administer the
17     program; and
18          ▸     provides minimum qualifications for a county or an individual seeking to participate
19     in the program.
20     Money Appropriated in this Bill:
21          None
22     Other Special Clauses:
23          None
24     Utah Code Sections Affected:
25     AMENDS:
26          63I-2-263, as last amended by Laws of Utah 2019, Chapters 182, 240, 246, 325, 370,
27     and 483

28     ENACTS:
29          63M-7-213, Utah Code Annotated 1953
30     

31     Be it enacted by the Legislature of the state of Utah:
32          Section 1. Section 63I-2-263 is amended to read:
33          63I-2-263. Repeal dates, Title 63A to Title 63N.
34          (1) On July 1, 2020:
35          (a) Subsection 63A-1-203(5)(a)(i) is repealed; and
36          (b) in Subsection 63A-1-203(5)(a)(ii), the language that states "appointed on or after
37     May 8, 2018," is repealed.
38          (2) Sections 63C-4a-307 and 63C-4a-309 are repealed January 1, 2020.
39          (3) Title 63C, Chapter 19, Higher Education Strategic Planning Commission is
40     repealed July 1, 2020.
41          (4) The following sections regarding the World War II Memorial Commission are
42     repealed on July 1, 2020:
43          (a) Section 63G-1-801;
44          (b) Section 63G-1-802;
45          (c) Section 63G-1-803; and
46          (d) Section 63G-1-804.
47          (5) In relation to the State Fair Park Committee, on January 1, 2021:
48          (a) Section 63H-6-104.5 is repealed; and
49          (b) Subsections 63H-6-104(8) and (9) are repealed.
50          (6) Section 63H-7a-303 is repealed on July 1, 2022.
51          (7) In relation to the Employability to Careers Program Board, on July 1, 2022:
52          (a) Subsection 63J-1-602.1(52) is repealed;
53          (b) Subsection 63J-4-301(1)(h), related to the review of data and metrics, is repealed;
54     and
55          (c) Title 63J, Chapter 4, Part 7, Employability to Careers Program, is repealed.
56          (8) Section 63J-4-708 is repealed January 1, 2023.
57          (9) Section 63M-7-211 is repealed December 31, 2026.
58          Section 2. Section 63M-7-213 is enacted to read:

59          63M-7-213. County Jail Drug Treatment Pilot Program.
60          (1) As used in this section:
61          (a) "Federally qualified health center" means the same as that term is defined in 42
62     U.S.C. Sec. 1395x.
63          (b) "Commission" means the Commission on Criminal and Juvenile Justice created in
64     Section 63M-7-203.
65          (c) "Program" means the County Jail Drug Treatment Pilot Program created in this
66     section.
67          (2) There is created the County Jail Drug Treatment Pilot Program for the purpose of
68     providing Naltrexone treatment to individuals who are or were recently incarcerated at a county
69     jail.
70          (3) (a) The commission shall administer the program in accordance with this section.
71          (b) The commission may, upon application by a county in accordance with Subsection
72     (4), approve the county to participate in the program if:
73          (i) the county has a population of 150,000 or less;
74          (ii) a federally qualified health center is located within the county;
75          (iii) one or more federally qualified health centers located in the county agree to
76     participate in the program in conjunction with the county; and
77          (iv) the county jail within the county has access to a health professional licensed to
78     draw blood, administer prescription drugs by injection, and offer medical advice.
79          (c) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the
80     commission shall establish a process by which the commission:
81          (i) reviews and approves an application for participation in the program;
82          (ii) coordinates with one or more Naltrexone providers to assist participating counties
83     in obtaining Naltrexone;
84          (iii) applies for grants that provide funding to support the administration of Naltrexone
85     to current or former qualifying inmates; and
86          (iv) oversees the administration of the program.
87          (4) To participate in the program, a county shall submit an application to the
88     commission no later than April 1, 2021, that includes:
89          (a) contact information for the individuals who will oversee and implement the

90     program at:
91          (i) the county;
92          (ii) the county jail; and
93          (iii) the federally qualified health facility; and
94          (b) the application materials required by the commission.
95          (5) An individual incarcerated at a county jail in a participating county may elect to
96     receive Naltrexone treatment under the program, if the individual:
97          (a) suffers an alcohol or opiate addiction;
98          (b) is of sufficient health to receive Naltrexone treatment, as determined by a qualified
99     health professional; and
100          (c) is currently incarcerated at the county jail and the county jail will have adequate
101     time to screen and advise the individual, in accordance with Subsection (7), before the county
102     jail releases the individual from incarceration.
103          (6) The Naltrexone treatment described in Subsection (5)(b) shall, to the extent
104     medically advisable, consist of:
105          (a) one injection administered at the county jail by a health professional, licensed as
106     described in Subsection (3)(b)(iv), within seven days before the day on which the county jail
107     releases the individual from incarceration; and
108          (b) five additional injections administered by a health professional, licensed as
109     described in Subsection (3)(b)(iv) and employed by a federally qualified health center, on a
110     monthly basis following the individual's release from incarceration.
111          (7) Before the first injection described in Subsection (6)(a), a health professional who
112     is licensed as described in Subsection (3)(b)(iv), shall:
113          (a) assess the individual's health to ensure the Naltrexone treatment is safe for the
114     individual; and
115          (b) fully advise the individual of all potential side effects and risks associated with the
116     Naltrexone treatment.
117          (8) (a) Before an individual receives the Naltrexone treatment under the program, the
118     individual shall agree to:
119          (i) attend a monthly appointment at a designated federally qualified health center to
120     receive a Naltrexone injection for five consecutive months; and

121          (ii) attend counseling as ordered by the court.
122          (b) A violation of the agreement described in Subsection (8)(a) may disqualify the
123     individual from participation in the program.
124          (9) If practicable, the participating county shall provide a case worker to oversee and
125     assist the individuals participating in the program.
126          (10) Naltrexone treatment administered under this program shall be funded or provided
127     by:
128          (a) available federal funding or grants;
129          (b) grants of Naltrexone provided by a non-governmental organization;
130          (c) an individual receiving Naltrexone treatment, through the individual's independent
131     financing or the individual's health benefit plan, as defined in Section 31A-1-301; or
132          (d) any other governmental or non-governmental organization that provides funding
133     for:
134          (i) treatment to an individual participating in the program; or
135          (ii) the program generally.
136          (11) The program begins on July 1, 2021, and ends on December 30, 2026.